// App-Quantinova.ai

17939 : Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease: Results From TRACER

Researchers

Presenter

  • Pierluigi Tricoci

Principal Investigators

  • Zhen Huang

  • Philip E Aylward

  • SAHMRI

  • Edmond Chen

  • Manesh R Patel

  • Kenneth W Mahaffey

  • David J Moliterno

  • Robert A Harrington

  • Peter Sinnaeve

  • John Strony

  • Frans Van de Werf

  • Harvey D White

  • Claes Held

  • Paul W Armstrong

Medical Centers

  • Flinders University Medical Centre, Adelaide, Australia

  • Duke Univ Medical Ctr/Duke Clinical Res Inst, Durham, NC

  • Univ. of Alberta, Edmonton, Alberta, Canada.

  • Gill Heart Inst and Univ of Kentucky, Lexington, KY

  • Uppsala Clinical Res Ctr, Uppsala Univ, Uppsala, Sweden

  • Green Lane Cardiovascular Service, Auckland, New Zealand

  • Duke Medcl Ctr, Durham, NC

  • Univ Hosps Leuven, Leuven, Belgium

Locations

  • Canada

  • Australia

  • United States

  • Belgium

  • Sweden

  • New Zealand

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Peripheral artery disease

  • Acute Coronary Syndromes

  • Myocardial infarction

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Vorapaxar

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved